Loading
companiesCompany
IASO Biotherapeutics
IASO Bio developed eque-cel, the fully human BCMA CAR-T for myeloma approved in China in 2023 and partnered with Innovent.
Also called: 驯鹿生物IASO Bio
Overview
IASO Biotherapeutics, based in Nanjing and Shanghai and founded in 2017, developed equecabtagene autoleucel, or eque-cel, the fully human BCMA CAR-T for multiple myeloma approved in China in 2023 and partnered with Innovent. The work was spun out of Tongji Hospital in Wuhan, eque-cel, sold as Fucaso, was approved in June 2023 on the FUMANBA-1 trial and holds FDA RMAT designation, and the pipeline includes CD19 and BCMA CAR-Ts for autoimmune disease and a CD19 and BCMA dual CAR-T. OnCo links it to CAR-T cell therapy, to the eque-cel record, to Innovent Biologics and to Tongji Hospital. Whether a Chinese-developed CAR-T can win approval in the United States on its own data is the open question. Equecabtagene autoleucel has its own page.
Headquarters
Nanjing / Shanghai, CN
Scorecard
All companies#286of 1244 companies, score 15
- approved products +6
- targets +2
- modalities +2
- regions +1
- registry trials +4
1 approved, 0 in phase 3, 0 earlier, 1 targets, 4 registry studies. Formula on the scorecards page.
Type
Website
Founded
2017
ApprovedCell therapy (autologous BCMA CAR-T, fully human binder)
Equecabtagene autoleucel · Fucaso
Equecabtagene autoleucel is a BCMA CAR-T from IASO Bio and Innovent, approved in China in June 2023 for multiple myeloma that has returned after at least three lines of treatment. In the FUMANBA-1 trial about 96% of infused patients responded, most with deep minimal-residual-disease-negative remissions and few severe cytokine release reactions; it competes with cilta-cel and zevor-cel in China.
Similar pages
- PersonMichael Yu (Yu De-Chao)
Shares Equecabtagene autoleucel, Innovent Biologics and the tag china.
- TrialORIENT-16
Shares Innovent Biologics and the tag china.
- TrialORIENT-32
Shares Innovent Biologics and the tag china.
- TrialORIENT-11
Shares Innovent Biologics and the tag china.
- InstitutionRenji Hospital, Shanghai Jiao Tong University
Shares CAR-T cell therapy and the tag china.
- TrialLUMMICAR STUDY 1
Shares CAR-T cell therapy and the tag china.
- InstitutionPeking University People's Hospital
Shares CAR-T cell therapy and the tag china.
- InstitutionInstitute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
Shares CAR-T cell therapy and the tag china.
fronts
technologies
drugs
ApprovedCell therapy (autologous BCMA CAR-T, fully human binder)
Equecabtagene autoleucel · Fucaso